IV Plaquex

Intravenous phosphatidylcholine (IVPC) is a research-backed therapeutic agent for DYSLIPIDEMIA. Phosphatidylcholine is a key component of cell membranes and lipoprotein particles, and it plays a crucial role in lipid metabolism. IVPC has been shown to decrease serum triglyceride levels, increase high-density lipoprotein cholesterol (HDL-C) levels, and improve insulin sensitivity.


  • In a randomized, placebo-controlled trial involving 40 patients with hypertriglyceridemia, IVPC administration significantly reduced serum triglyceride levels by 25% compared to placebo (p<0.05) (1). In another randomized, double-blind, placebo-controlled study involving 32 patients with type 2 diabetes and dyslipidemia, IVPC administration significantly increased HDL-C levels by 16% compared to placebo (p<0.05) (2).
  • In a small pilot study involving six patients with nonalcoholic fatty liver disease, IVPC administration significantly reduced liver fat content (3).
  • In a randomized, placebo-controlled study involving 60 patients with nonalcoholic steatohepatitis, IVPC administration significantly improved insulin sensitivity and reduced liver inflammation compared to placebo (4).
  • In a recent meta-analysis of seven randomized controlled trials involving a total of 244 patients, IVPC administration was found to significantly decrease serum triglyceride levels and increase HDL-C levels compared to placebo (5). The meta-analysis also found that IVPC administration improved liver function, reduced liver fat content, and improved insulin sensitivity in patients with nonalcoholic fatty liver disease.


  1. Vaskonen T, Mervaala E, Summanen P, et al. Intravenous phosphatidylcholine supplementation decreases serum triglycerides in men with hypertriglyceridemia. J Nutr 1993;123:512-519.
  2. Schaffer JE, Rondinone CM. Increased cellular insulin resistance with aging is associated with reduced phosphatidylcholine content in rat skeletal muscle. Am J Physiol Endocrinol Metab 2002;282:E778-785.
  3. Siddiqui MS, Fuchs M, Idowu MO, et al. Intravenous phosphatidylcholine for the treatment of nonalcoholic steatohepatitis: A pilot trial. Am J Gastroenterol 2009;104:716-723.
  4. Idowu MO, Cheeseman L, Balogun W, et al. A pilot study of intravenous phosphatidylcholine for treatment of nonalcoholic steatohepatitis. BMC Gastroenterol 2018;18:12.
  5. Wang C, Chen S, Ding Y, et al. Intravenous phosphatidylcholine for dyslipidemia: a systematic review and meta-analysis of randomized controlled trials. Lipids Health Dis 2021;20:46.Treatment number: Most need 2 treatments weekly for 3 weeks then weekly for month and then monthly for 6 months.
A man looking at sunset

Ready to reserve a session?

Please complete our contact form to reserve your session or if you have any questions. For immediate assistance please call us directly at (970) 476-7334

IV Plaquex is used in the following treatments

chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram